JANX (Janux Therapeutics) Interest Expense: $0.00 Mil (TTM As of Mar. 2026)


JANX Janux Therapeutics Inc JANX
46 GF Score
Price $16.08
GF Value $41.69
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Janux Therapeutics Interest Expense?

Janux Therapeutics JANX -1.98% 46 Interest Expense is $0.00 Mil as of Mar. 2026. GuruFocus rates JANX with a GF Score™ of 46/100 and a GF Value™ of $41.69 (Possible Value Trap). The stock has 5 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Janux Therapeutics's interest expense for the three months ended in Mar. 2026 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Janux Therapeutics's Operating Income for the three months ended in Mar. 2026 was $ -34.21 Mil. Janux Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $ 0.00 Mil. GuruFocus does not calculate Janux Therapeutics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Janux Therapeutics  (NAS:JANX) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Janux Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-34.21 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $19.10 Mil.

Janux Therapeutics's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

GuruFocus does not calculate Janux Therapeutics's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Janux Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

Janux Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Janux Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Janux Therapeutics Interest Expense Chart

Janux Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Janux Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
JANX
46GF Score
Janux Therapeutics Inc JANX
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Janux Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $0.00 Mil mean?
Janux Therapeutics (JANX) has a Interest Expense of $0.00 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Janux Therapeutics and its competitors.
Is Janux Therapeutics' Interest Expense too high?
Janux Therapeutics' current Interest Expense is $0.00 Mil. Overall, Janux Therapeutics has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Janux Therapeutics' Interest Expense compare to SLDB and TBPH?
Janux Therapeutics' Interest Expense of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Janux Therapeutics and its competitors. Janux Therapeutics's current Interest Expense is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Janux Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Janux Therapeutics (JANX) is currently considered Possible Value Trap. The stock's GF Value™ is $41.69, compared to a current price of $16.08 — trading 61.4% below its estimated fair value. The current Interest Expense is $0.00 Mil. Janux Therapeutics' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Janux Therapeutics (JANX), the current Interest Expense is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Janux Therapeutics (JANX) Overvalued in 2026?

Based on GuruFocus' analysis, Janux Therapeutics stock appears to be undervalued. The current stock price of $16.08 is trading 61.4% below its estimated GF Value™ of $41.69. GuruFocus considers Janux Therapeutics to be Possible Value Trap.

Key valuation signals for JANX:

  • Interest Expense: $0.00 Mil
  • GF Value™: $41.69 vs. price of $16.08 (61.4% below fair value)
  • GF Score™: 46/100 with 5 warning signs

No single metric tells the full story. See the JANX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Janux Therapeutics Business Description

Address 10955 Vista Sorrento Parkway, Suite 200, San Diego, CA, USA, 92130
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
46GF Score

Get the complete analysis for JANX

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.08
Price
$41.69
GF Value